Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine
- PMID: 37830088
- PMCID: PMC10565861
- DOI: 10.3389/fneur.2023.1263535
Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine
Abstract
Background: Refractory migraine is a poorly described complication of migraine in which migraine has chronified and become resistant to standard treatments. The true prevalence is unknown, but medication resistance is common in headache clinic patient populations. Given the lack of response to treatment, this patient population is extremely difficult to treat with limited guidance in the literature.
Objective: To review the diagnostic, pathophysiological, and management challenges in the refractory migraine population.
Discussion: There are no accepted, or even ICHD-3 appendix, diagnostic criteria for refractory migraine though several proposed criteria exist. Current proposed criteria often have low bars for refractoriness while also not meeting the needs of pediatrics, lower socioeconomic status, and developing nations. Pathophysiology is unknown but can be hypothesized as a persistent "on" state as a progression from chronic migraine with increasing central sensitization, but there may be heterogeneity in the underlying pathophysiology. No guidelines exist for treatment of refractory migraine; once all guideline-based treatments are tried, treatment consists of n-of-1 treatment trials paired with non-pharmacologic management.
Conclusion: Refractory migraine is poorly described diagnostically, its pathophysiology can only be guessed at by extension of chronic migraine, and treatment is more the art than science of medicine. Navigating care of this refractory population will require multidisciplinary care models and an emphasis on future research to answer these unknowns.
Keywords: chronic daily headache; chronic migraine; diagnosis; intractable migraine; management; refractory migraine; resistant migraine.
Copyright © 2023 Robblee.
Conflict of interest statement
JR discloses grant support from Barrow Neurological foundation, investigator support from Eli Lilly and Abbvie, paid advisory board for Abbvie, speaker for Impel, as well as paid Editorial relationship with MedLink Neurology and Neurodiem. JR also discloses that a family member has partial ownership of Scottsdale Providence Recovery Center.
Similar articles
-
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.J Headache Pain. 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4. J Headache Pain. 2021. PMID: 34006218 Free PMC article.
-
Refractory headache: classification and nomenclature.Headache. 2008 Jun;48(6):783-90. doi: 10.1111/j.1526-4610.2008.01150.x. Headache. 2008. PMID: 18549356
-
Refractory migraine in a headache clinic population.BMC Neurol. 2011 Aug 1;11:94. doi: 10.1186/1471-2377-11-94. BMC Neurol. 2011. PMID: 21806790 Free PMC article.
-
Migraine Progression: A Systematic Review.Headache. 2019 Mar;59(3):306-338. doi: 10.1111/head.13459. Epub 2018 Dec 27. Headache. 2019. PMID: 30589090
-
What Are We Missing in the Diagnostic Criteria for Migraine?Curr Pain Headache Rep. 2018 Oct 5;22(12):84. doi: 10.1007/s11916-018-0733-1. Curr Pain Headache Rep. 2018. PMID: 30291572 Review.
Cited by
-
Benefit of Dietary Supplementation of Nutraceuticals as an Integrative Approach for Management of Migraine: Evidence From Preclinical and Clinical Studies.Curr Pain Headache Rep. 2024 May;28(5):373-381. doi: 10.1007/s11916-024-01230-w. Epub 2024 Mar 2. Curr Pain Headache Rep. 2024. PMID: 38430311 Free PMC article. Review.
-
Efficacy of Desvenlafaxine in Reducing Migraine Frequency and Severity: A Retrospective Study.J Clin Med. 2024 Aug 30;13(17):5156. doi: 10.3390/jcm13175156. J Clin Med. 2024. PMID: 39274369 Free PMC article.
-
First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.J Headache Pain. 2024 Sep 27;25(1):160. doi: 10.1186/s10194-024-01873-5. J Headache Pain. 2024. PMID: 39333875 Free PMC article.
-
New perspectives on migraine treatment: a review of the mechanisms and effects of complementary and alternative therapies.Front Neurol. 2024 May 9;15:1372509. doi: 10.3389/fneur.2024.1372509. eCollection 2024. Front Neurol. 2024. PMID: 38784897 Free PMC article. Review.
References
-
- Schulman EA, Lake AE, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, et al. . Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society. Headache. (2008) 48:778–82. doi: 10.1111/j.1526-4610.2008.01132.x, PMID: - DOI - PubMed
-
- Wöber C, Wessely P, Austrian Consensus Group on Refractory Chronic Migraine . Comment on: Martelletti et al. Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain. (2014) 15:77. doi: 10.1186/1129-2377-15-77, PMID: - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources